Common use of Population Estimates Clause in Contracts

Population Estimates. The population estimates of the sex- and race-specific, as well as sex- and ethnicity/race-specific groups in five-year age categories, were used as denominators in the formulation of rates.2 These population estimates of Illinois for all races, whites, blacks and Asian/other races from 1986 through 2012, and for Hispanics, non-Hispanics, non-Hispanic white and non-Hispanic black for 1990 through 2012 were obtained from both the intercensal and Vintage 2013 bridged-race post censal population estimates files. Population estimates by age, sex, race and Hispanic origin were produced by the U.S. Bureau of Census Population Estimates Program (xxxx://xxx.xxxxxx.xxx/popest/index.html), in collaboration with the National Center for Health Statistics, and with support from the National Cancer Institute (NCI) through an interagency agreement. The population estimates incorporate intercensal (for 2000‐2009) and Vintage 2013 (for 2010‐2012) bridged single‐race estimates are derived from the original multiple race categories in the 2000 census (as specified in the 1997 Office of Management and Budget standards for the collection of data on race and ethnicity xxxx://xxx.xxxxxxxxxx.xxx/omb/inforeg_statpolicy). The bridged single‐race estimates and a description of the methodology used to develop them appear on the National Center for Health Statistics website (xxxx://xxx.xxx.xxx/nchs/nvss/bridged_race.htm). The intercensal estimates provide an adjustment of previous population estimates based on the actual 2010 census results (xxxx://xxx.xxxxxx.xxx/popest/methodology/2013-natstcopr-meth.pdf).3,4 Previous estimates utilized prior to the availability of the 2010 census data were prone to increased error as the time from the actual 2000 census increased. At the national level, estimates using both the 2000 census and the 2010 census are not very different from the previous estimates. However, there are more significant differences at the state and county levels that may result in changes to cancer incidence rates when one compares this report to earlier versions. Changes in rates also could be attributable to the addition of cases reported late. DEFINITIONS Cancer Site Coding for Incidence Data: Although the anatomic site and morphology for cancer cases diagnosed prior to 2001 were coded using the International Classification of Diseases for Oncology version 2 (ICD-O-2)5 and for cancer cases diagnosed in 2001 through 2009, the version 3 (ICD-O-3),6 all ICD-O-2 coded cases were converted to version 3 codes. The current version of the histologies Web-based query data utilizes the ICD-O-3 recode with adjustment for WHO 2008 hematopoietic. SEER-NCI recommends this site recode scheme (Site Recode ICD-O-3/WHO 2008) be used for any data containing cases diagnosed in 2010 or later years. In the interests of comparability to other national, state and registry specific data, subsequent versions of the Web-based query data containing cases diagnosed in 2010 or later will indeed use the SEER Site Recode ICD-O- 3/WHO 2008. For a complete listing, see Appendix B of the annual state report (see Illinois State Cancer Incidence Review and Update). Data at the county level in this application are aggregated into 24 major site groups and at the ZIP codes level into 11 site groups. These standardized classification schemes allow direct comparisons of Illinois data with international, national and state publications. Several definitional changes occurred in some histologies and behaviors in ICD-O-3 that affected the inclusion and exclusion of reportable cancers diagnosed beginning in 2001. These changes may affect the comparability of data between rates prior to 2001 and 2001 or later. The changes predominately affected leukemias, lymphomas and cancer of the ovary. Several cancers that previously were not coded as malignant in ICD-O-2 are coded as malignant in ICD-O-3. For example, Myolodysplastic syndrome (MDS) and chronic myeloproliferative disease (CMPD) are considered malignant cancer in ICD-O-3, as are papillary ependymomas and papillary meningiomas, which according to ICD-O-3, are included in the “Brain and Nervous System” and “All Cancers Combined” categories. Some endometrial tumors also are classified as malignant in ICD-O-3. Conversely, some low malignant potential tumors of the ovary and pilocytic astrocytomas are no longer coded as malignant in ICD-O-3. Overall, these changes would have a slight impact on incidence of a specific cancer site; however, it might result in a noticeable increase in cancer incidence rates for “All Cancers Combined.” In addition, both Kaposi sarcoma and mesothelioma are classified as separate site groups within the SEER recode. This change has a slight impact on cancer incidence rates for a few specific cancers, compared to using the previous site grouping method. Counts and rates were calculated for invasive cancers only, with the exception of in situ cancer of the bladder. Although counts and rates for breast cancer in situ are displayed in a separate table, these cases were not included in any counts or rates of all sites combined incidence. Confidentiality of the incidence data is maintained by aggregating data within individual records into categories, the number of which depend on the size of the geographic area. Individual year of diagnosis is available for the Illinois data files, however, for the county, ZIP code, Cook County and stage files, the diagnosis year is a five-year aggregate (1988-1992, 1993-1997, 1998-2002 (this and prior groups not available for the Cook County file), 2003-2007 and 2008-2012).

Population Estimates. The population estimates of the sex- and race-specific, as well as sex- and ethnicity/race-specific groups in five-year age categories, were used as denominators in the formulation of rates.2 rates. These population estimates of Illinois for all races, whitesWhites, blacks Blacks, and Asian/other races from 1986 through 20122019, and for Hispanics, non-Hispanics, non-Hispanic white White, and non-Hispanic black Black for 1990 through 2012 2019 were obtained from both the intercensal and Vintage 2013 2020 bridged-race post censal population estimates files. Population estimates by age, sex, race race, and Hispanic origin were produced by the U.S. United States Bureau of Census Population Estimates Program (xxxx://xxx.xxxxxx.xxx/popest/index.html), in collaboration with the National Center for Health Statistics, and with support from the National Cancer Institute (NCI) through an interagency agreement. The population estimates incorporate intercensal (for 2000‐2009) and Vintage 2013 2020 (for 2010‐20122010‐2019) bridged single‐race estimates are derived from the original multiple race categories in the 2000 census and 2010 Censuses (as specified in the 1997 Office of Management and Budget standards for the collection of data on race and ethnicity xxxx://xxx.xxxxxxxxxx.xxx/omb/inforeg_statpolicyethnicity). The bridged single‐race estimates and a description of the methodology used to develop them appear on the National Center for Health Statistics website (xxxx://xxx.xxx.xxx/nchs/nvss/bridged_race.htm)website. The intercensal estimates provide an adjustment of previous population estimates based on the actual 2010 census results (xxxx://xxx.xxxxxx.xxx/popest/methodology/2013-natstcopr-meth.pdf).3,4 results.7,8 Previous estimates utilized prior to the availability of the 2010 census data were prone to increased error as the time from the actual 2000 census increased. At the national level, estimates using both the 2000 census and the 2010 census are not very different from the previous estimates. However, there are more significant differences at the state and county levels that may result in changes to cancer incidence mortality rates when one compares this report to earlier versions. Changes in rates also could be attributable to the addition of cases reported late. DEFINITIONS Cancer Site Coding for Incidence Data: Although the anatomic site and morphology for cancer cases diagnosed prior to 2001 were coded using the International Classification of Diseases for Oncology version 2 (ICD-O-2)5 and for cancer cases diagnosed in 2001 through 2009, the version 3 (ICD-O-3),6 all ICD-O-2 coded cases were converted to version 3 codes. The current version of the histologies Web-based query data utilizes the ICD-O-3 recode with adjustment for WHO 2008 hematopoietic. SEER-NCI recommends this site recode scheme (Site Recode ICD-O-3/WHO 2008) be used for any data containing cases diagnosed in 2010 or later years. In the interests of comparability to other national, state and registry specific data, subsequent versions of the Web-based query data containing cases diagnosed in 2010 or later will indeed use the SEER Site Recode ICD-O- 3/WHO 2008. For a complete listing, see Appendix B of the annual state report (see Illinois State Cancer Incidence Review and Update). Data at the county level in this application are aggregated into 24 major site groups and at the ZIP codes level into 11 site groups. These standardized classification schemes allow direct comparisons of Illinois data with international, national and state publications. Several definitional changes occurred in some histologies and behaviors in ICD-O-3 that affected the inclusion and exclusion of reportable cancers diagnosed beginning in 2001. These changes may affect the comparability of data between rates prior to 2001 and 2001 or later. The changes predominately affected leukemias, lymphomas and cancer of the ovary. Several cancers that previously were not coded as malignant in ICD-O-2 are coded as malignant in ICD-O-3. For example, Myolodysplastic syndrome (MDS) and chronic myeloproliferative disease (CMPD) are considered malignant cancer in ICD-O-3, as are papillary ependymomas and papillary meningiomas, which according to ICD-O-3, are included in the “Brain and Nervous System” and “All Cancers Combined” categories. Some endometrial tumors also are classified as malignant in ICD-O-3. Conversely, some low malignant potential tumors of the ovary and pilocytic astrocytomas are no longer coded as malignant in ICD-O-3. Overall, these changes would have a slight impact on incidence of a specific cancer site; however, it might result in a noticeable increase in cancer incidence rates for “All Cancers Combined.” In addition, both Kaposi sarcoma and mesothelioma are classified as separate site groups within the SEER recode. This change has a slight impact on cancer incidence rates for a few specific cancers, compared to using the previous site grouping method. Counts and rates were calculated for invasive cancers only, with the exception of in situ cancer of the bladder. Although counts and rates for breast cancer in situ are displayed in a separate table, these cases were not included in any counts or rates of all sites combined incidence. Confidentiality of the incidence data is maintained by aggregating data within individual records into categories, the number of which depend on the size of the geographic area. Individual year of diagnosis is available for the Illinois data files, however, for the county, ZIP code, Cook County and stage files, the diagnosis year is a five-year aggregate (1988-1992, 1993-1997, 1998-2002 (this and prior groups not available for the Cook County file), 2003-2007 and 2008-2012).

Population Estimates. The population estimates of the sex- and race-specific, as well as sex- and ethnicity/race-specific groups in five-year age categories, were used as denominators in the formulation of rates.2 rates. These population estimates of Illinois for all races, whitesWhites, blacks Blacks, and Asian/other races from 1986 through 20122020, and for Hispanics, non-Hispanics, non-Hispanic white White, and non-Hispanic black Black for 1990 through 2012 2020 were obtained from both the intercensal and Vintage 2013 2020 bridged-race post censal population estimates files. Population estimates by age, sex, race race, and Hispanic origin were produced by the U.S. United States Bureau of Census Population Estimates Program (xxxx://xxx.xxxxxx.xxx/popest/index.html), in collaboration with the National Center for Health Statistics, and with support from the National Cancer Institute (NCI) through an interagency agreement. The population estimates incorporate intercensal (for 2000‐2009) and Vintage 2013 2020 (for 2010‐20122010‐2020) bridged single‐race estimates are derived from the original multiple race categories in the 2000 census and 2010 Censuses (as specified in the 1997 Office of Management and Budget standards for the collection of data on race and ethnicity xxxx://xxx.xxxxxxxxxx.xxx/omb/inforeg_statpolicyethnicity). The bridged single‐race estimates and a description of the methodology used to develop them appear on the National Center for Health Statistics website (xxxx://xxx.xxx.xxx/nchs/nvss/bridged_race.htm)website. The intercensal estimates provide an adjustment of previous population estimates based on the actual 2010 census results (xxxx://xxx.xxxxxx.xxx/popest/methodology/2013-natstcopr-meth.pdf).3,4 results.7,8 Previous estimates utilized prior to the availability of the 2010 census data were prone to increased error as the time from the actual 2000 census increased. At the national level, estimates using both the 2000 census and the 2010 census are not very different from the previous estimates. However, there are more significant differences at the state and county levels that may result in changes to cancer incidence mortality rates when one compares this report to earlier versions. Changes in rates also could be attributable to the addition of cases reported late. DEFINITIONS Cancer Site Coding for Incidence Data: Although the anatomic site and morphology for cancer cases diagnosed prior to 2001 were coded using the International Classification of Diseases for Oncology version 2 (ICD-O-2)5 and for cancer cases diagnosed in 2001 through 2009, the version 3 (ICD-O-3),6 all ICD-O-2 coded cases were converted to version 3 codes. The current version of the histologies Web-based query data utilizes the ICD-O-3 recode with adjustment for WHO 2008 hematopoietic. SEER-NCI recommends this site recode scheme (Site Recode ICD-O-3/WHO 2008) be used for any data containing cases diagnosed in 2010 or later years. In the interests of comparability to other national, state and registry specific data, subsequent versions of the Web-based query data containing cases diagnosed in 2010 or later will indeed use the SEER Site Recode ICD-O- 3/WHO 2008. For a complete listing, see Appendix B of the annual state report (see Illinois State Cancer Incidence Review and Update). Data at the county level in this application are aggregated into 24 major site groups and at the ZIP codes level into 11 site groups. These standardized classification schemes allow direct comparisons of Illinois data with international, national and state publications. Several definitional changes occurred in some histologies and behaviors in ICD-O-3 that affected the inclusion and exclusion of reportable cancers diagnosed beginning in 2001. These changes may affect the comparability of data between rates prior to 2001 and 2001 or later. The changes predominately affected leukemias, lymphomas and cancer of the ovary. Several cancers that previously were not coded as malignant in ICD-O-2 are coded as malignant in ICD-O-3. For example, Myolodysplastic syndrome (MDS) and chronic myeloproliferative disease (CMPD) are considered malignant cancer in ICD-O-3, as are papillary ependymomas and papillary meningiomas, which according to ICD-O-3, are included in the “Brain and Nervous System” and “All Cancers Combined” categories. Some endometrial tumors also are classified as malignant in ICD-O-3. Conversely, some low malignant potential tumors of the ovary and pilocytic astrocytomas are no longer coded as malignant in ICD-O-3. Overall, these changes would have a slight impact on incidence of a specific cancer site; however, it might result in a noticeable increase in cancer incidence rates for “All Cancers Combined.” In addition, both Kaposi sarcoma and mesothelioma are classified as separate site groups within the SEER recode. This change has a slight impact on cancer incidence rates for a few specific cancers, compared to using the previous site grouping method. Counts and rates were calculated for invasive cancers only, with the exception of in situ cancer of the bladder. Although counts and rates for breast cancer in situ are displayed in a separate table, these cases were not included in any counts or rates of all sites combined incidence. Confidentiality of the incidence data is maintained by aggregating data within individual records into categories, the number of which depend on the size of the geographic area. Individual year of diagnosis is available for the Illinois data files, however, for the county, ZIP code, Cook County and stage files, the diagnosis year is a five-year aggregate (1988-1992, 1993-1997, 1998-2002 (this and prior groups not available for the Cook County file), 2003-2007 and 2008-2012).

Population Estimates. The population estimates of the sex- and race-specific, as well as sex- and ethnicity/race-race- specific groups in five-year age categories, were used as denominators in the formulation of rates.2 rates. These population estimates of Illinois for all races, whites, blacks blacks, and Asian/other races from 1986 through 20122017, and for Hispanics, non-Hispanics, non-Hispanic white white, and non-Hispanic black for 1990 through 2012 2017 were obtained from both the intercensal and Vintage 2013 2018 bridged-race post censal population estimates files. Population estimates by age, sex, race race, and Hispanic origin were produced by the U.S. United States Bureau of Census Population Estimates Program (xxxx://xxx.xxxxxx.xxx/popest/index.html), in collaboration with the National Center for Health Statistics, and with support from the National Cancer Institute (NCI) through an interagency agreement. The population estimates incorporate intercensal (for 2000‐20092000-2009) and Vintage 2013 2018 (for 2010‐20122010-2017) bridged single‐race single-race estimates are derived from the original multiple race categories in the 2000 census and 2010 Censuses (as specified in the 1997 Office of Management and Budget standards for the collection of data on race and ethnicity xxxx://xxx.xxxxxxxxxx.xxx/omb/inforeg_statpolicyethnicity). The bridged single‐race single-race estimates and a description of the methodology used to develop them appear on the National Center for Health Statistics website (xxxx://xxx.xxx.xxx/nchs/nvss/bridged_race.htm)website. The intercensal estimates provide an adjustment of previous population estimates based on the actual 2010 census results (xxxx://xxx.xxxxxx.xxx/popest/methodology/2013-natstcopr-meth.pdf).3,4 results.7,8 Previous estimates utilized prior to the availability of the 2010 census data were prone to increased error as the time from the actual 2000 census increased. At the national level, estimates using both the 2000 census and the 2010 census are not very different from the previous estimates. However, there are more significant differences at the state and county levels that may result in changes to cancer incidence rates when one compares this report to earlier versions. Changes in rates also could be attributable to the addition of cases reported late. DEFINITIONS Cancer Site Coding for Incidence Data: Although the anatomic site and morphology for cancer cases diagnosed prior to 2001 were coded using the International Classification of Diseases for Oncology version 2 (ICD-O-2)5 and for cancer cases diagnosed in 2001 through 2009, the version 3 (ICD-O-3),6 all ICD-O-2 coded cases were converted to version 3 codes. The current version of the histologies Web-based query data utilizes the ICD-O-3 recode with adjustment for WHO 2008 hematopoietic. SEER-NCI recommends this site recode scheme (Site Recode ICD-O-3/WHO 2008) be used for any data containing cases diagnosed in 2010 or later years. In the interests of comparability to other national, state and registry specific data, subsequent versions of the Web-based query data containing cases diagnosed in 2010 or later will indeed use the SEER Site Recode ICD-O- 3/WHO 2008. For a complete listing, see Appendix B of the annual state report (see Illinois State Cancer Incidence Review and Update). Data at the county level in this application are aggregated into 24 major site groups and at the ZIP codes level into 11 site groups. These standardized classification schemes allow direct comparisons of Illinois data with international, national and state publications. Several definitional changes occurred in some histologies and behaviors in ICD-O-3 that affected the inclusion and exclusion of reportable cancers diagnosed beginning in 2001. These changes may affect the comparability of data between rates prior to 2001 and 2001 or later. The changes predominately affected leukemias, lymphomas and cancer of the ovary. Several cancers that previously were not coded as malignant in ICD-O-2 are coded as malignant in ICD-O-3. For example, Myolodysplastic syndrome (MDS) and chronic myeloproliferative disease (CMPD) are considered malignant cancer in ICD-O-3, as are papillary ependymomas and papillary meningiomas, which according to ICD-O-3, are included in the “Brain and Nervous System” and “All Cancers Combined” categories. Some endometrial tumors also are classified as malignant in ICD-O-3. Conversely, some low malignant potential tumors of the ovary and pilocytic astrocytomas are no longer coded as malignant in ICD-O-3. Overall, these changes would have a slight impact on incidence of a specific cancer site; however, it might result in a noticeable increase in cancer incidence rates for “All Cancers Combined.” In addition, both Kaposi sarcoma and mesothelioma are classified as separate site groups within the SEER recode. This change has a slight impact on cancer incidence rates for a few specific cancers, compared to using the previous site grouping method. Counts and rates were calculated for invasive cancers only, with the exception of in situ cancer of the bladder. Although counts and rates for breast cancer in situ are displayed in a separate table, these cases were not included in any counts or rates of all sites combined incidence. Confidentiality of the incidence data is maintained by aggregating data within individual records into categories, the number of which depend on the size of the geographic area. Individual year of diagnosis is available for the Illinois data files, however, for the county, ZIP code, Cook County and stage files, the diagnosis year is a five-year aggregate (1988-1992, 1993-1997, 1998-2002 (this and prior groups not available for the Cook County file), 2003-2007 and 2008-2012).

Population Estimates. The population estimates of the sex- and race-specific, as well as sex- and ethnicity/race-specific groups in five-year age categories, were used as denominators in the formulation of rates.2 rates. These population estimates of Illinois for all races, whites, blacks blacks, and Asian/other races from 1986 through 20122017, and for Hispanics, non-Hispanics, non-Hispanic white white, and non-Hispanic black for 1990 through 2012 2017 were obtained from both the intercensal and Vintage 2013 2018 bridged-race post censal population estimates files. Population estimates by age, sex, race race, and Hispanic origin were produced by the U.S. United States Bureau of Census Population Estimates Program (xxxx://xxx.xxxxxx.xxx/popest/index.html), in collaboration with the National Center for Health Statistics, and with support from the National Cancer Institute (NCI) through an interagency agreement. The population estimates incorporate intercensal (for 2000‐20092000-2009) and Vintage 2013 2018 (for 2010‐20122010-2017) bridged single‐race single-race estimates are derived from the original multiple race categories in the 2000 census and 2010 Censuses (as specified in the 1997 Office of Management and Budget standards for the collection of data on race and ethnicity xxxx://xxx.xxxxxxxxxx.xxx/omb/inforeg_statpolicyethnicity). The bridged single‐race single-race estimates and a description of the methodology used to develop them appear on the National Center for Health Statistics website (xxxx://xxx.xxx.xxx/nchs/nvss/bridged_race.htm)website. The intercensal estimates provide an adjustment of previous population estimates based on the actual 2010 census results (xxxx://xxx.xxxxxx.xxx/popest/methodology/2013-natstcopr-meth.pdf).3,4 results.7,8 Previous estimates utilized prior to the availability of the 2010 census data were prone to increased error as the time from the actual 2000 census increased. At the national level, estimates using both the 2000 census and the 2010 census are not very different from the previous estimates. However, there are more significant differences at the state and county levels that may result in changes to cancer incidence rates when one compares this report to earlier versions. Changes in rates also could be attributable to the addition of cases reported late. DEFINITIONS Cancer Site Coding for Incidence Data: Although the anatomic site and morphology for cancer cases diagnosed prior to 2001 were coded using the International Classification of Diseases for Oncology version 2 (ICD-O-2)5 and for cancer cases diagnosed in 2001 through 2009, the version 3 (ICD-O-3),6 all ICD-O-2 coded cases were converted to version 3 codes. The current version of the histologies ISCR Web-based query data utilizes the ICD-O-3 recode with adjustment for WHO 2008 hematopoietic. SEER-NCI recommends this site recode scheme (Site Recode ICD-O-3/WHO 2008) be used for any data containing cases diagnosed in 2010 or later years. In the interests of comparability to other national, state and registry specific data, subsequent versions of the Web-based query data containing cases diagnosed in 2010 or later will indeed use the SEER Site Recode ICD-O- 3O-3/WHO 2008. For a complete listing, see Appendix B of the annual state report (see Illinois State Cancer Incidence Review and Update). Data at the county level in this application are aggregated into 24 major site groups and at the ZIP codes level into 11 site groups. These standardized classification schemes allow direct comparisons of Illinois data with international, national national, and state publications. Several definitional changes occurred in some histologies and behaviors in ICD-O-3 that affected the inclusion and exclusion of reportable cancers diagnosed beginning in 2001. These changes may affect the comparability of data between rates prior to 2001 and 2001 or later. The changes predominately affected leukemias, lymphomas lymphomas, and cancer of the ovary. Several cancers that previously were not coded as malignant in ICD-O-2 are coded as malignant in ICD-O-3. For example, Myolodysplastic syndrome (MDS) and chronic myeloproliferative disease (CMPD) are considered malignant cancer in ICD-O-3, as are papillary ependymomas and papillary meningiomas, which according to ICD-O-3, are included in the “Brain and Nervous System” and “All Cancers Combined” categories. Some endometrial tumors also are classified as malignant in ICD-O-3. Conversely, some low malignant potential tumors of the ovary and pilocytic astrocytomas are no longer coded as malignant in ICD-O-3. OverallBecause of the way cancers are grouped in this report, these changes would have a slight or little impact on incidence of a specific cancer site; however, it might result in a noticeable increase in cancer incidence rates for “All Cancers Combined.” In addition, both Kaposi sarcoma and mesothelioma are classified as separate site groups within the SEER recode. This change has a slight impact on cancer incidence rates for a few specific cancers, compared to using the previous site grouping method. Counts and rates were calculated for invasive cancers only, with the exception of in situ cancer of the bladder. Although counts and rates for breast cancer in situ are displayed in a separate table, these cases were not included in any counts or rates of all sites combined incidence. Confidentiality of the incidence data is maintained by aggregating data within individual records into categories, the number of which depend on the size of the geographic area. Individual year of diagnosis is available for the Illinois data files, however, for the county, ZIP code, Cook County and stage files, the diagnosis year is a five-year aggregate (1988-1992, 1993-1997, 1998-2002 2002, 2003-2007 (this and prior groups not available for the Cook County file), 2003-2007 and 2008-2012, and 2013-2017).

Population Estimates. The population estimates of the sex- and race-specific, as well as sex- and ethnicity/race-race- specific groups groups, in five-year age categories, categories were used as denominators for rate calculations in the formulation of rates.2 these data. These population estimates of Illinois and Illinois counties for all races, whites, blacks and Asian/other races from 1986 through 2012, 2010 and for Hispanics, non-Hispanics, non-Hispanic white Hispanics and non-Hispanic black Hispanics for 1990 through 2012 2010, were obtained from the SEER program based on United States Bureau of Census population estimates.2 They represent a modification of both the intercensal and Vintage 2013 bridged-race post censal 2011 annual time series of July 1 county population estimates files. Population estimates by age, sex, race race, and Hispanic origin were produced by the U.S. United States Bureau of Census Population Estimates Program (xxxx://xxx.xxxxxx.xxx/popest/index.htmlxxxx://xxx.xxxxxx.xxx/popest/index.html ), in collaboration with the National Center for Health Statistics, and with support from the National Cancer Institute (NCI) through an interagency agreement. The population estimates incorporate new intercensal (for July 1, 2000‐2009) and Vintage 2013 2011 (for 2010‐2012July 1, 2010‐2011) bridged single‐race estimates that are derived from the original multiple race categories in the 2000 census Census (as specified in the 1997 Office of Management and Budget standards for the collection of data on race and ethnicity xxxx://xxx.xxxxxxxxxx.xxx/omb/inforeg_statpolicy(xxxx://xxx.xxxxxxxxxx.xxx/omb/inforeg_statpolicy/#dr ). The bridged single‐race estimates and a description of the methodology used to develop them appear on the National Center for Health Statistics website (xxxx://xxx.xxx.xxx/nchs/nvss/bridged_race.htm). The new intercensal estimates provide an adjustment of previous population estimates based on the actual 2010 census Census results (xxxx://xxx.xxxxxx.xxx/popest/methodology/2013-natstcopr-meth.pdf).3,4 Previous xxxx://xxx.xxxxxx.xxx/popest/methodology/2000‐2010_Intercensal_Estimates_Methodology.pdf)3,4. Since the previous population estimates utilized prior to were extrapolated from the availability of the 2010 census data 2000 Census, they were prone to increased error as the time from the actual 2000 census Census increased. At the national level, the new estimates using both the 2000 census and the 2010 census are not very different from the previous estimates. However, there are more significant differences at the state and county levels that may result in changes to cancer incidence rates when one compares this report to earlier versions. Illinois population estimates from Vintage 2009 data for calendar year 2009 were compared to those produced using the modified intercensal estimates data for the same year. Use of methods in the intercensal estimates file resulted in a 0.9 percent decrease in Illinois’ total population. The methods resulted in total population changes ranging from ‐8.2 percent to +11.3 percent among individual Illinois counties. The new intercensal methods put Illinois’ cancer rate 0.08 percent higher than what was calculated previously using Vintage 2009. While these changes did little to impact Illinois’ statewide cancer rate, the methods may play a role in changes realized by specific counties. However, differences in incidence rates may not solely be the result of changes in population estimates. Changes in rates also could be attributable to the addition of cases reported late. DEFINITIONS Cancer Site Coding for Incidence Data: Although the anatomic site and morphology for cancer cases diagnosed prior to 2001 were coded using the International Classification of Diseases for Oncology version 2 (ICD-O-2)5 and for cancer cases diagnosed in 2001 through 2009, 2009 the version 3 (ICD-O-3),6 all ICD-O-2 coded cases were converted to version 3 codes. The current version of the histologies Web-web based query data utilizes the ICD-O-3 recode with adjustment for WHO 2008 hematopoietichematopoietic histologies. SEER-NCI recommends that this site recode scheme (Site Recode ICD-O-3/WHO 2008) be used for any data containing cases diagnosed in 2010 or later years. In the interests of comparability to other national, state and registry specific data, data subsequent versions of the Web-web based query data containing cases diagnosed in 2010 or later will indeed use the SEER Site Recode ICD-O- 3O-3/WHO 2008. For a complete listing, listing please see Appendix B of the annual state report (see Illinois State Cancer Incidence and Mortality Review and Update, 1986-2010). Data at a state level are available on request for these site groups. Data at the state and county level in this application are aggregated into 24 major site groups and at the ZIP codes level into 11 site groups. These standardized classification schemes allow direct comparisons of Illinois data with international, national and state publications. Several definitional changes occurred in some histologies and behaviors in ICD-O-3 that affected the inclusion and exclusion of reportable cancers diagnosed beginning in 2001. These changes may affect the comparability of data between rates prior to 2001 and 2001 or later. The changes predominately affected leukemias, lymphomas lymphomas, and cancer of the ovary. Several cancers that previously were not coded as malignant in ICD-O-2 are coded as malignant in ICD-O-3. For example, Myolodysplastic syndrome (MDS) and chronic myeloproliferative disease (CMPD) are considered malignant cancer in ICD-O-3, as are papillary ependymomas and papillary meningiomasmeningiomas which, which according to ICD-O-3, are included in the “Brain and Nervous System” and “All Cancers Combined” categories. Some endometrial tumors also are classified as malignant in ICD-O-3. Conversely, some low malignant potential tumors of the ovary and pilocytic astrocytomas are no longer coded as malignant in ICD-O-3. Overall, these changes would have a slight impact on incidence of a specific cancer site; however, it might result in a noticeable increase in cancer incidence rates for “All Cancers Combined.” In addition, both Kaposi sarcoma and mesothelioma are classified as separate site groups within the SEER recode. This change has a slight impact on cancer incidence rates for a few specific cancers, compared to using the previous site grouping method. Counts and rates were calculated for invasive cancers only, with the exception of in situ cancer of the bladder. Although counts and rates for breast cancer in situ are displayed in a separate table, these cases were not included in any counts or rates of all sites combined incidence. Confidentiality of the incidence data is maintained by aggregating data within individual records into categories, the number of which depend on the size of the geographic area. Individual year of diagnosis is available for the Illinois data files, however, for the county, ZIP code, Cook County and stage files, the diagnosis year is a five-year aggregate (1988-1992, 1993-1997, 1998-2002 (this and prior groups not available for the Cook County file), 2003-2007 and 2008-2012).O-

Population Estimates. The population estimates of the sex- and race-specific, as well as sex- and ethnicity/race-specific groups in five-year age categories, were used as denominators in the formulation of rates.2 rates. These population estimates of Illinois for all races, whites, blacks blacks, and Asian/other races from 1986 through 20122016, and for Hispanics, non-Hispanics, non-Hispanic white white, and non-Hispanic black for 1990 through 2012 2016 were obtained from both the intercensal and Vintage 2013 2017 bridged-race post censal population estimates files. Population estimates by age, sex, race race, and Hispanic origin were produced by the U.S. United States Bureau of Census Population Estimates Program (xxxx://xxx.xxxxxx.xxx/popest/index.html), in collaboration with the National Center for Health Statistics, and with support from the National Cancer Institute (NCI) through an interagency agreement. The population estimates incorporate intercensal (for 2000‐2009) and Vintage 2013 2017 (for 2010‐20122010‐2016) bridged single‐race estimates are derived from the original multiple race categories in the 2000 census and 2010 Censuses (as specified in the 1997 Office of Management and Budget standards for the collection of data on race and ethnicity xxxx://xxx.xxxxxxxxxx.xxx/omb/inforeg_statpolicyethnicity). The bridged single‐race estimates and a description of the methodology used to develop them appear on the National Center for Health Statistics website (xxxx://xxx.xxx.xxx/nchs/nvss/bridged_race.htm)website. The intercensal estimates provide an adjustment of previous population estimates based on the actual 2010 census results (xxxx://xxx.xxxxxx.xxx/popest/methodology/2013-natstcopr-meth.pdf).3,4 xxxxx://xxx0.xxxxxx.xxx/programs-surveys/popest/technical- documentation/methodology/2010-2017/2017-est-relnotes.pdf).7,8 Previous estimates utilized prior to the availability of the 2010 census data were prone to increased error as the time from the actual 2000 census increased. At the national level, estimates using both the 2000 census and the 2010 census are not very different from the previous estimates. However, there are more significant differences at the state and county levels that may result in changes to cancer incidence rates when one compares this report to earlier versions. Changes in rates also could be attributable to the addition of cases reported late. DEFINITIONS Cancer Site Coding for Incidence Data: Although the anatomic site and morphology for cancer cases diagnosed prior to 2001 were coded using the International Classification of Diseases for Oncology version 2 (ICD-O-2)5 and for cancer cases diagnosed in 2001 through 2009, the version 3 (ICD-O-3),6 all ICD-O-2 coded cases were converted to version 3 codes. The current version of the histologies ISCR Web-based query data utilizes the ICD-O-3 recode with adjustment for WHO 2008 hematopoietic. SEER-NCI recommends this site recode scheme (Site Recode ICD-O-3/WHO 2008) be used for any data containing cases diagnosed in 2010 or later years. In the interests of comparability to other national, state and registry specific data, subsequent versions of the Web-based query data containing cases diagnosed in 2010 or later will indeed use the SEER Site Recode ICD-O- 3O-3/WHO 2008. For a complete listing, see Appendix B of the annual state report (see Illinois State Cancer Incidence Review and Update). Data at the county level in this application are aggregated into 24 major site groups and at the ZIP codes level into 11 site groups. These standardized classification schemes allow direct comparisons of Illinois data with international, national national, and state publications. Several definitional changes occurred in some histologies and behaviors in ICD-O-3 that affected the inclusion and exclusion of reportable cancers diagnosed beginning in 2001. These changes may affect the comparability of data between rates prior to 2001 and 2001 or later. The changes predominately affected leukemias, lymphomas lymphomas, and cancer of the ovary. Several cancers that previously were not coded as malignant in ICD-O-2 are coded as malignant in ICD-O-3. For example, Myolodysplastic syndrome (MDS) and chronic myeloproliferative disease (CMPD) are considered malignant cancer in ICD-O-3, as are papillary ependymomas and papillary meningiomas, which according to ICD-O-3, are included in the “Brain and Nervous System” and “All Cancers Combined” categories. Some endometrial tumors also are classified as malignant in ICD-O-3. Conversely, some low malignant potential tumors of the ovary and pilocytic astrocytomas are no longer coded as malignant in ICD-O-3. OverallBecause of the way cancers are grouped in this report, these changes would have a slight or little impact on incidence of a specific cancer site; however, it might result in a noticeable increase in cancer incidence rates for “All Cancers Combined.” In addition, both Kaposi sarcoma and mesothelioma are classified as separate site groups within the SEER recode. This change has a slight impact on cancer incidence rates for a few specific cancers, compared to using the previous site grouping method. Counts and rates were calculated for invasive cancers only, with the exception of in situ cancer of the bladder. Although counts and rates for breast cancer in situ are displayed in a separate table, these cases were not included in any counts or rates of all sites combined incidence. Confidentiality of the incidence data is maintained by aggregating data within individual records into categories, the number of which depend on the size of the geographic area. Individual year of diagnosis is available for the Illinois data files, however, for the county, ZIP code, Cook County and stage files, the diagnosis year is a five-year aggregate (19881992-19921996, 19931997-19972001, 19982002-2002 2006 (this and prior groups not available for the Cook County file), 20032007-2007 2011, and 20082012-20122016).

Population Estimates. The population estimates of the sex- and race-specific, as well as sex- and ethnicity/race-specific groups in five-year age categories, were used as denominators in the formulation of rates.2 These population estimates of Illinois for all races, whites, blacks and Asian/other races from 1986 through 20122011, and for Hispanics, non-Hispanics, non-Hispanic white and non-Hispanic black for 1990 through 2012 2011 were obtained from both the intercensal and Vintage 2013 2012 bridged-race post censal population estimates files. Population estimates by age, sex, race and Hispanic origin were produced by the U.S. Bureau of Census Population Estimates Program (xxxx://xxx.xxxxxx.xxx/popest/index.html), in collaboration with the National Center for Health Statistics, and with support from the National Cancer Institute (NCI) through an interagency agreement. The population estimates incorporate intercensal (for 2000‐2009) and Vintage 2013 2012 (for 2010‐20122010‐2011) bridged single‐race estimates are derived from the original multiple race categories in the 2000 census (as specified in the 1997 Office of Management and Budget standards for the collection of data on race and ethnicity xxxx://xxx.xxxxxxxxxx.xxx/omb/inforeg_statpolicyxxxx://xxx.xxxxxxxxxx.xxx/omb/inforeg_statpolicy/#dr). The bridged single‐race estimates and a description of the methodology used to develop them appear on the National Center for Health Statistics website (xxxx://xxx.xxx.xxx/nchs/nvss/bridged_race.htm). The new intercensal estimates provide an adjustment of previous population estimates based on the actual 2010 census results (xxxx://xxx.xxxxxx.xxx/popest/methodology/2013-natstcopr-meth.pdf).3,4 xxxx://xxx.xxxxxx.xxx/popest/methodology/2000‐2010_Intercensal_Estimates_Methodology.pdf).3,4 Previous estimates utilized prior to the availability of the 2010 census data were prone to increased error as the time from the actual 2000 census increased. At the national level, estimates using both the 2000 census and the 2010 census are not very different from the previous estimates. However, there are more significant differences at the state and county levels that may result in changes to cancer incidence rates when one compares this report to earlier versions. Changes in rates also could be attributable to the addition of cases reported late. DEFINITIONS Cancer Site Coding for Incidence Data: Although the anatomic site and morphology for cancer cases diagnosed prior to 2001 were coded using the International Classification of Diseases for Oncology version 2 (ICD-O-2)5 and for cancer cases diagnosed in 2001 through 2009, the version 3 (ICD-O-3),6 all ICD-O-2 coded cases were converted to version 3 codes. The current version of the histologies Web-based query data utilizes the ICD-O-3 recode with adjustment for WHO 2008 hematopoietichematopoietic histologies. SEER-NCI recommends this site recode scheme (Site Recode ICD-O-3/WHO 2008) be used for any data containing cases diagnosed in 2010 or later years. In the interests of comparability to other national, state and registry specific data, subsequent versions of the Web-based query data containing cases diagnosed in 2010 or later will indeed use the SEER Site Recode ICD-O- 3O-3/WHO 2008. For a complete listing, see Appendix B of the annual state report (see Illinois State Cancer Incidence and Mortality Review and Update, 1986-2011). Data at the county level in this application are aggregated into 24 major site groups and at the ZIP codes level into 11 site groups. These standardized classification schemes allow direct comparisons of Illinois data with international, national and state publications. Several definitional changes occurred in some histologies and behaviors in ICD-O-3 that affected the inclusion and exclusion of reportable cancers diagnosed beginning in 2001. These changes may affect the comparability of data between rates prior to 2001 and 2001 or later. The changes predominately affected leukemias, lymphomas and cancer of the ovary. Several cancers that previously were not coded as malignant in ICD-O-2 are coded as malignant in ICD-O-3. For example, Myolodysplastic syndrome (MDS) and chronic myeloproliferative disease (CMPD) are considered malignant cancer in ICD-O-3, as are papillary ependymomas and papillary meningiomas, which according to ICD-O-3, are included in the “Brain and Nervous System” and “All Cancers Combined” categories. Some endometrial tumors also are classified as malignant in ICD-O-3. Conversely, some low malignant potential tumors of the ovary and pilocytic astrocytomas are no longer coded as malignant in ICD-O-3. Overall, these changes would have a slight impact on incidence of a specific cancer site; however, it might result in a noticeable increase in cancer incidence rates for “All Cancers Combined.” In addition, both Kaposi sarcoma and mesothelioma are classified as separate site groups within the SEER recode. This change has a slight impact on cancer incidence rates for a few specific cancers, compared to using the previous site grouping method. Counts and rates were calculated for invasive cancers only, with the exception of in situ cancer of the bladder. Although counts and rates for breast cancer in situ are displayed in a separate table, these cases were not included in any counts or rates of all sites combined incidence. Confidentiality of the incidence data is maintained by aggregating data within individual records into categories, the number of which depend on the size of the geographic area. Individual year of diagnosis is available for the Illinois data files, however, for the county, ZIP code, Cook County and stage files, the diagnosis year is a five-year aggregate (19881987-1992, 1993-1997, 1998-2002 1991 (this and prior groups not available for the Cook County fileCounty), 20031992-2007 1996, 1997-2001, 2002-2006 and 20082007-20122011).

Population Estimates. The population estimates of the sex- and race-specific, as well as sex- and ethnicity/race-specific groups in five-year age categories, were used as denominators in the formulation of rates.2 rates. These population estimates of Illinois for all races, whites, blacks blacks, and Asian/other races from 1986 through 20122020, and for Hispanics, non-Hispanics, non-Hispanic white white, and non-Hispanic black for 1990 through 2012 2020 were obtained from both the intercensal and Vintage 2013 2020 bridged-race post censal population estimates files. Population estimates by age, sex, race race, and Hispanic origin were produced by the U.S. United States Bureau of Census Population Estimates Program (xxxx://xxx.xxxxxx.xxx/popest/index.html), in collaboration with the National Center for Health Statistics, and with support from the National Cancer Institute (NCI) through an interagency agreement. The population estimates incorporate intercensal (for 2000‐2009) and Vintage 2013 2020 (for 2010‐20122010‐2020) bridged single‐race estimates are derived from the original multiple race categories in the 2000 census and 2010 Censuses (as specified in the 1997 Office of Management and Budget standards for the collection of data on race and ethnicity xxxx://xxx.xxxxxxxxxx.xxx/omb/inforeg_statpolicyethnicity). The bridged single‐race estimates and a description of the methodology used to develop them appear on the National Center for Health Statistics website (xxxx://xxx.xxx.xxx/nchs/nvss/bridged_race.htm)website. The intercensal estimates provide an adjustment of previous population estimates based on the actual 2010 census results (xxxx://xxx.xxxxxx.xxx/popest/methodology/2013-natstcopr-meth.pdf).3,4 results.7,8 Previous estimates utilized prior to the availability of the 2010 census data were prone to increased error as the time from the actual 2000 census increased. At the national level, estimates using both the 2000 census and the 2010 census are not very different from the previous estimates. However, there are more significant differences at the state and county levels that may result in changes to cancer incidence rates when one compares this report to earlier versions. Changes in rates also could be attributable to the addition of cases reported late. DEFINITIONS Cancer Site Coding for Incidence Data: Although the anatomic site and morphology for cancer cases diagnosed prior to 2001 were coded using the International Classification of Diseases for Oncology version 2 (ICD-O-2)5 and for cancer cases diagnosed in 2001 through 2009, the version 3 (ICD-O-3),6 all ICD-O-2 coded cases were converted to version 3 codes. The current version of the histologies ISCR Web-based query data utilizes the ICD-O-3 recode with adjustment for WHO 2008 hematopoietic. SEER-NCI recommends this site recode scheme (Site Recode ICD-O-3/WHO 2008) be used for any data containing cases diagnosed in 2010 or later years. In the interests of comparability to other national, state and registry specific data, subsequent versions of the Web-based query data containing cases diagnosed in 2010 or later will indeed use the SEER Site Recode ICD-O- 3O-3/WHO 2008. For a complete listing, see Appendix B of the annual state report (see Illinois State Cancer Incidence Review and Update). Data at the county level in this application are aggregated into 24 major site groups and at the ZIP codes level into 11 site groups. These standardized classification schemes allow direct comparisons of Illinois data with international, national national, and state publications. Several definitional changes occurred in some histologies and behaviors in ICD-O-3 that affected the inclusion and exclusion of reportable cancers diagnosed beginning in 2001. These changes may affect the comparability of data between rates prior to 2001 and 2001 or later. The changes predominately affected leukemias, lymphomas lymphomas, and cancer of the ovary. Several cancers that previously were not coded as malignant in ICD-O-2 are coded as malignant in ICD-O-3. For example, Myolodysplastic Myelodysplastic syndrome (MDS) and chronic myeloproliferative disease (CMPD) are considered malignant cancer in ICD-O-3, as are papillary ependymomas and papillary meningiomas, which according to ICD-O-3, are included in the “Brain and Nervous System” and “All Cancers Combined” categories. Some endometrial tumors also are classified as malignant in ICD-O-3. Conversely, some low malignant potential tumors of the ovary and pilocytic astrocytomas are no longer coded as malignant in ICD-O-3. OverallBecause of the way cancers are grouped in this report, these changes would have a slight or little impact on incidence of a specific cancer site; however, it might result in a noticeable increase in cancer incidence rates for “All Cancers Combined.” In addition, both Kaposi sarcoma and mesothelioma are classified as separate site groups within the SEER recode. This change has a slight impact on cancer incidence rates for a few specific cancers, compared to using the previous site grouping method. Counts and rates were calculated for invasive cancers only, with the exception of in situ cancer of the bladder. Although counts and rates for breast cancer in situ are displayed in a separate table, these cases were not included in any counts or rates of all sites combined incidence. Confidentiality of the incidence data is maintained by aggregating data within individual records into categories, the number of which depend on the size of the geographic area. Individual year of diagnosis is available for the Illinois data files, however, for the county, ZIP code, Cook County and stage files, the diagnosis year is a five-year aggregate (19881996-19922000, 19932001-19972005, 19982006-2002 2010 (this and prior groups not available for the Cook County file), 20032011-2007 2015, and 20082016-20122020).

Population Estimates. The population estimates of the sex- and race-specific, specific as well as sex- and ethnicity/race-race- specific groups in five-year age categories, categories were used as denominators in the formulation of rates.2 These population estimates of Illinois for all races, whites, blacks and Asian/other races from 1986 through 20122011, and for Hispanics, non-Hispanics, non-Hispanic white and non-Hispanic black for 1990 through 2012 2011 were obtained from both the intercensal and Vintage 2013 2012 bridged-race post censal population estimates files. Population estimates by age, sex, race and Hispanic origin were produced by the U.S. Bureau of Census Population Estimates Program (xxxx://xxx.xxxxxx.xxx/popest/index.html), in collaboration with the National Center for Health Statistics, and with support from the National Cancer Institute (NCI) through an interagency agreement. The population estimates incorporate intercensal (for 2000‐2009) and Vintage 2013 2012 (for 2010‐20122010‐2011) bridged single‐race estimates are derived from the original multiple race categories in the 2000 census (as specified in the 1997 Office of Management and Budget standards for the collection of data on race and ethnicity xxxx://xxx.xxxxxxxxxx.xxx/omb/inforeg_statpolicyxxxx://xxx.xxxxxxxxxx.xxx/omb/inforeg_statpolicy/#dr). The bridged single‐race estimates and a description of the methodology used to develop them appear on the National Center for Health Statistics website (xxxx://xxx.xxx.xxx/nchs/nvss/bridged_race.htm). The new intercensal estimates provide an adjustment of previous population estimates based on the actual 2010 census Census results (xxxx://xxx.xxxxxx.xxx/popest/methodology/2013-natstcopr-meth.pdf).3,4 xxxx://xxx.xxxxxx.xxx/popest/methodology/2000‐2010_Intercensal_Estimates_Methodology.pdf)3,4. Previous estimates utilized prior to the availability of the 2010 census data were prone to increased error as the time from the actual 2000 census increased. At the national level, estimates using both the 2000 census and the 2010 census are not very different from the previous estimates. However, there are more significant differences at the state and county levels that may result in changes to cancer incidence rates when one compares this report to earlier versions. Changes in rates also could be attributable to the addition of cases reported late. DEFINITIONS Cancer Site Coding for Incidence Data: Although the anatomic site and morphology for cancer cases diagnosed prior to 2001 were coded using the International Classification of Diseases for Oncology version 2 (ICD-O-2)5 and for cancer cases diagnosed in 2001 through 2009, the version 3 (ICD-O-3),6 all ICD-O-2 coded cases were converted to version 3 codes. The current version of the histologies Web-based query data utilizes the ICD-O-3 recode with adjustment for WHO 2008 hematopoietic. SEER-NCI recommends this site recode scheme (Site Recode ICD-O-3/WHO 2008) be used for any data containing cases diagnosed in 2010 or later years. In the interests of comparability to other national, state and registry specific data, subsequent versions of the Web-based query data containing cases diagnosed in 2010 or later will indeed use the SEER Site Recode ICD-O- 3/WHO 2008. For a complete listing, see Appendix B of the annual state report (see Illinois State Cancer Incidence Review and Update). Data at the county level in this application are aggregated into 24 major site groups and at the ZIP codes level into 11 site groups. These standardized classification schemes allow direct comparisons of Illinois data with international, national and state publications. Several definitional changes occurred in some histologies and behaviors in ICD-O-3 that affected the inclusion and exclusion of reportable cancers diagnosed beginning in 2001. These changes may affect the comparability of data between rates prior to 2001 and 2001 or later. The changes predominately affected leukemias, lymphomas and cancer of the ovary. Several cancers that previously were not coded as malignant in ICD-O-2 are coded as malignant in ICD-O-3. For example, Myolodysplastic syndrome (MDS) and chronic myeloproliferative disease (CMPD) are considered malignant cancer in ICD-O-3, as are papillary ependymomas and papillary meningiomas, which according to ICD-O-3, are included in the “Brain and Nervous System” and “All Cancers Combined” categories. Some endometrial tumors also are classified as malignant in ICD-O-3. Conversely, some low malignant potential tumors of the ovary and pilocytic astrocytomas are no longer coded as malignant in ICD-O-3. Overall, these changes would have a slight impact on incidence of a specific cancer site; however, it might result in a noticeable increase in cancer incidence rates for “All Cancers Combined.” In addition, both Kaposi sarcoma and mesothelioma are classified as separate site groups within the SEER recode. This change has a slight impact on cancer incidence rates for a few specific cancers, compared to using the previous site grouping method. Counts and rates were calculated for invasive cancers only, with the exception of in situ cancer of the bladder. Although counts and rates for breast cancer in situ are displayed in a separate table, these cases were not included in any counts or rates of all sites combined incidence. Confidentiality of the incidence data is maintained by aggregating data within individual records into categories, the number of which depend on the size of the geographic area. Individual year of diagnosis is available for the Illinois data files, however, for the county, ZIP code, Cook County and stage files, the diagnosis year is a five-year aggregate (1988-1992, 1993-1997, 1998-2002 (this and prior groups not available for the Cook County file), 2003-2007 and 2008-2012).

Population Estimates. The population estimates of the sex- and race-specific, as well as sex- and ethnicity/race-specific groups in five-year age categories, were used as denominators in the formulation of rates.2 rates. These population estimates of Illinois for all races, whites, blacks blacks, and Asian/other races from 1986 through 20122019, and for Hispanics, non-Hispanics, non-Hispanic white white, and non-Hispanic black for 1990 through 2012 2019 were obtained from both the intercensal and Vintage 2013 2020 bridged-race post censal population estimates files. Population estimates by age, sex, race race, and Hispanic origin were produced by the U.S. United States Bureau of Census Population Estimates Program (xxxx://xxx.xxxxxx.xxx/popest/index.html), in collaboration with the National Center for Health Statistics, and with support from the National Cancer Institute (NCI) through an interagency agreement. The population estimates incorporate intercensal (for 2000‐2009) and Vintage 2013 2020 (for 2010‐20122010‐2019) bridged single‐race estimates are derived from the original multiple race categories in the 2000 census and 2010 Censuses (as specified in the 1997 Office of Management and Budget standards for the collection of data on race and ethnicity xxxx://xxx.xxxxxxxxxx.xxx/omb/inforeg_statpolicyethnicity). The bridged single‐race estimates and a description of the methodology used to develop them appear on the National Center for Health Statistics website (xxxx://xxx.xxx.xxx/nchs/nvss/bridged_race.htm)website. The intercensal estimates provide an adjustment of previous population estimates based on the actual 2010 census results (xxxx://xxx.xxxxxx.xxx/popest/methodology/2013-natstcopr-meth.pdf).3,4 results.7,8 Previous estimates utilized prior to the availability of the 2010 census data were prone to increased error as the time from the actual 2000 census increased. At the national level, estimates using both the 2000 census and the 2010 census are not very different from the previous estimates. However, there are more significant differences at the state and county levels that may result in changes to cancer incidence rates when one compares this report to earlier versions. Changes in rates also could be attributable to the addition of cases reported late. DEFINITIONS Cancer Site Coding for Incidence Data: Although the anatomic site and morphology for cancer cases diagnosed prior to 2001 were coded using the International Classification of Diseases for Oncology version 2 (ICD-O-2)5 and for cancer cases diagnosed in 2001 through 2009, the version 3 (ICD-O-3),6 all ICD-O-2 coded cases were converted to version 3 codes. The current version of the histologies ISCR Web-based query data utilizes the ICD-O-3 recode with adjustment for WHO 2008 hematopoietic. SEER-NCI recommends this site recode scheme (Site Recode ICD-O-3/WHO 2008) be used for any data containing cases diagnosed in 2010 or later years. In the interests of comparability to other national, state and registry specific data, subsequent versions of the Web-based query data containing cases diagnosed in 2010 or later will indeed use the SEER Site Recode ICD-O- 3O-3/WHO 2008. For a complete listing, see Appendix B of the annual state report (see Illinois State Cancer Incidence Review and Update). Data at the county level in this application are aggregated into 24 major site groups and at the ZIP codes level into 11 site groups. These standardized classification schemes allow direct comparisons of Illinois data with international, national national, and state publications. Several definitional changes occurred in some histologies and behaviors in ICD-O-3 that affected the inclusion and exclusion of reportable cancers diagnosed beginning in 2001. These changes may affect the comparability of data between rates prior to 2001 and 2001 or later. The changes predominately affected leukemias, lymphomas lymphomas, and cancer of the ovary. Several cancers that previously were not coded as malignant in ICD-O-2 are coded as malignant in ICD-O-3. For example, Myolodysplastic Myelodysplastic syndrome (MDS) and chronic myeloproliferative disease (CMPD) are considered malignant cancer in ICD-O-3, as are papillary ependymomas and papillary meningiomas, which according to ICD-O-3, are included in the “Brain and Nervous System” and “All Cancers Combined” categories. Some endometrial tumors also are classified as malignant in ICD-O-3. Conversely, some low malignant potential tumors of the ovary and pilocytic astrocytomas are no longer coded as malignant in ICD-O-3. OverallBecause of the way cancers are grouped in this report, these changes would have a slight or little impact on incidence of a specific cancer site; however, it might result in a noticeable increase in cancer incidence rates for “All Cancers Combined.” In addition, both Kaposi sarcoma and mesothelioma are classified as separate site groups within the SEER recode. This change has a slight impact on cancer incidence rates for a few specific cancers, compared to using the previous site grouping method. Counts and rates were calculated for invasive cancers only, with the exception of in situ cancer of the bladder. Although counts and rates for breast cancer in situ are displayed in a separate table, these cases were not included in any counts or rates of all sites combined incidence. Confidentiality of the incidence data is maintained by aggregating data within individual records into categories, the number of which depend on the size of the geographic area. Individual year of diagnosis is available for the Illinois data files, however, for the county, ZIP code, Cook County and stage files, the diagnosis year is a five-year aggregate (19881995-19921999, 19932000-19972004, 19982005-2002 2009 (this and prior groups not available for the Cook County file), 20032010-2007 2014, and 20082015-20122019).